Los Angeles Capital Management LLC Raises Position in Alnylam Pharmaceuticals, Inc. $ALNY

Los Angeles Capital Management LLC raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 50.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 240,052 shares of the biopharmaceutical company’s stock after buying an additional 80,658 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $95,457,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. iA Global Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 979.5% during the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after acquiring an additional 16,133 shares during the last quarter. Perpetual Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $2,004,000. Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 2.0% during the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 24.2% during the third quarter. Envestnet Asset Management Inc. now owns 118,964 shares of the biopharmaceutical company’s stock valued at $54,248,000 after acquiring an additional 23,168 shares during the last quarter. Finally, Linden Advisors LP purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $6,550,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the transaction, the insider directly owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 7,740 shares of company stock valued at $2,420,214. 0.86% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $303.05 on Friday. The stock has a fifty day simple moving average of $307.66 and a two-hundred day simple moving average of $349.36. Alnylam Pharmaceuticals, Inc. has a 1-year low of $283.10 and a 1-year high of $495.55. The firm has a market cap of $40.46 billion, a price-to-earnings ratio of 82.80 and a beta of 0.29. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the company earned ($0.44) earnings per share. Alnylam Pharmaceuticals’s revenue was up 96.4% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ALNY shares. Wells Fargo & Company increased their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research report on Friday, May 1st. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Wall Street Zen raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $463.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.